199 related articles for article (PubMed ID: 22382829)
41. Oral Administration of Polaprezinc Attenuates Fluorouracil-induced Intestinal Mucositis in a Mouse Model.
Liu Z; Xie W; Li M; Teng N; Liang X; Zhang Z; Yang Z; Wang X
Basic Clin Pharmacol Toxicol; 2017 Dec; 121(6):480-486. PubMed ID: 28667794
[TBL] [Abstract][Full Text] [Related]
42. Mucosal ulcerogenic action of monochloramine in rat stomachs: effects of polaprezinc and sucralfate.
Kato S; Nishiwaki H; Konaka A; Takeuchi K
Dig Dis Sci; 1997 Oct; 42(10):2156-63. PubMed ID: 9365151
[TBL] [Abstract][Full Text] [Related]
43. Effects of L-carnosine and its zinc complex (Polaprezinc) on pressure ulcer healing.
Sakae K; Agata T; Kamide R; Yanagisawa H
Nutr Clin Pract; 2013 Oct; 28(5):609-16. PubMed ID: 23835365
[TBL] [Abstract][Full Text] [Related]
44. Applicability of zinc complex of L-carnosine for medical use.
Matsukura T; Tanaka H
Biochemistry (Mosc); 2000 Jul; 65(7):817-23. PubMed ID: 10951100
[TBL] [Abstract][Full Text] [Related]
45. Effects of polaprezinc on lipid peroxidation, neutrophil accumulation, and TNF-alpha expression in rats with aspirin-induced gastric mucosal injury.
Naito Y; Yoshikawa T; Yagi N; Matsuyama K; Yoshida N; Seto K; Yoneta T
Dig Dis Sci; 2001 Apr; 46(4):845-51. PubMed ID: 11330422
[TBL] [Abstract][Full Text] [Related]
46. Efficacy of zinc-carnosine chelate compound, Polaprezinc, enemas in patients with ulcerative colitis.
Itagaki M; Saruta M; Saijo H; Mitobe J; Arihiro S; Matsuoka M; Kato T; Ikegami M; Tajiri H
Scand J Gastroenterol; 2014 Feb; 49(2):164-72. PubMed ID: 24286534
[TBL] [Abstract][Full Text] [Related]
47. Improvement of Dysgeusia by Polaprezinc, a Zinc-L-carnosine, in Outpatients Receiving Cancer Chemotherapy.
Fujii H; Hirose C; Ishihara M; Iihara H; Imai H; Tanaka Y; Matsuhashi N; Takahashi T; Yamaguchi K; Yoshida K; Suzuki A
Anticancer Res; 2018 Nov; 38(11):6367-6373. PubMed ID: 30396959
[TBL] [Abstract][Full Text] [Related]
48. Polaprezinc protects human colon cells from oxidative injury induced by hydrogen peroxide: relevant to cytoprotective heat shock proteins.
Ohkawara T; Nishihira J; Nagashima R; Takeda H; Asaka M
World J Gastroenterol; 2006 Oct; 12(38):6178-81. PubMed ID: 17036391
[TBL] [Abstract][Full Text] [Related]
49. Absorption mechanism of polaprezinc (zinc L-carnosine complex) by an everted sac method.
Furuta S; Toyama S; Sano H
Xenobiotica; 1994 Nov; 24(11):1085-94. PubMed ID: 7701850
[TBL] [Abstract][Full Text] [Related]
50. Basal protrusion of ulcers induced by endoscopic submucosal dissection (ESD) during treatment with proton pump inhibitors, and the suppressive effects of polaprezinc.
Inaba T; Ishikawa S; Toyokawa T; Ishikawa H; Miyahara K; Wato M; Kawai K; Okada H; Yamamoto K
Hepatogastroenterology; 2010; 57(99-100):678-84. PubMed ID: 20698249
[TBL] [Abstract][Full Text] [Related]
51. Oral zinc supplementation reduces the erythropoietin responsiveness index in patients on hemodialysis.
Kobayashi H; Abe M; Okada K; Tei R; Maruyama N; Kikuchi F; Higuchi T; Soma M
Nutrients; 2015 May; 7(5):3783-95. PubMed ID: 25988769
[TBL] [Abstract][Full Text] [Related]
52. Polaprezinc prevents oral mucositis associated with radiochemotherapy in patients with head and neck cancer.
Watanabe T; Ishihara M; Matsuura K; Mizuta K; Itoh Y
Int J Cancer; 2010 Oct; 127(8):1984-90. PubMed ID: 20104529
[TBL] [Abstract][Full Text] [Related]
53. Polaprezinc down-regulates proinflammatory cytokine-induced nuclear factor-kappaB activiation and interleukin-8 expression in gastric epithelial cells.
Shimada T; Watanabe N; Ohtsuka Y; Endoh M; Kojima K; Hiraishi H; Terano A
J Pharmacol Exp Ther; 1999 Oct; 291(1):345-52. PubMed ID: 10490923
[TBL] [Abstract][Full Text] [Related]
54. Polaprezinc inhibits liver fibrosis and proliferation in hepatocellular carcinoma.
Ye J; Zhang Z; Zhu L; Lu M; Li Y; Zhou J; Lu X; Du Q
Mol Med Rep; 2017 Oct; 16(4):5523-5528. PubMed ID: 28849143
[TBL] [Abstract][Full Text] [Related]
55. Drug repositioning of polaprezinc for bone fracture healing.
Ko EA; Park YJ; Yoon DS; Lee KM; Kim J; Jung S; Lee JW; Park KH
Commun Biol; 2022 May; 5(1):462. PubMed ID: 35577977
[TBL] [Abstract][Full Text] [Related]
56. Prognostic factors of recovery with medication in patients with taste disorders.
Nomura Y; Toi T; Ikeda M; Ikeda A; Tanaka M; Oshima T
PLoS One; 2020; 15(10):e0237270. PubMed ID: 33001974
[TBL] [Abstract][Full Text] [Related]
57. Reactive oxygen species-quenching and anti-apoptotic effect of polaprezinc on indomethacin-induced small intestinal epithelial cell injury.
Omatsu T; Naito Y; Handa O; Mizushima K; Hayashi N; Qin Y; Harusato A; Hirata I; Kishimoto E; Okada H; Uchiyama K; Ishikawa T; Takagi T; Yagi N; Kokura S; Ichikawa H; Yoshikawa T
J Gastroenterol; 2010 Jul; 45(7):692-702. PubMed ID: 20174833
[TBL] [Abstract][Full Text] [Related]
58. Changes in tissue contents of zinc, copper and iron in rats and beagle dogs treated with polaprezinc.
Yamaguchi I; Shibata K; Takei M; Matsuda K
J Toxicol Sci; 1996 Aug; 21(3):177-87. PubMed ID: 8887886
[TBL] [Abstract][Full Text] [Related]
59. Polaprezinc (Zinc L-carnosine) is a potent inducer of anti-oxidative stress enzyme, heme oxygenase (HO)-1 - a new mechanism of gastric mucosal protection.
Ueda K; Ueyama T; Oka M; Ito T; Tsuruo Y; Ichinose M
J Pharmacol Sci; 2009 Jul; 110(3):285-94. PubMed ID: 19542683
[TBL] [Abstract][Full Text] [Related]
60. Polaprezinc combined with clarithromycin-based triple therapy for Helicobacter pylori-associated gastritis: A prospective, multicenter, randomized clinical trial.
Tan B; Luo HQ; Xu H; Lv NH; Shi RH; Luo HS; Li JS; Ren JL; Zou YY; Li YQ; Ji F; Fang JY; Qian JM
PLoS One; 2017; 12(4):e0175625. PubMed ID: 28407007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
